{"name":"Hydra Biosciences","permalink":"hydra-biosciences","crunchbase_url":"http://www.crunchbase.com/company/hydra-biosciences","homepage_url":"http://www.hydrabiosciences.com","blog_url":"","blog_feed_url":"","twitter_username":"","category_code":"biotech","number_of_employees":null,"founded_year":null,"founded_month":null,"founded_day":null,"deadpooled_year":null,"deadpooled_month":null,"deadpooled_day":null,"deadpooled_url":null,"tag_list":"","alias_list":"","email_address":"info@hydrabiosciences.com","phone_number":"617-494-5230","description":"Biopharmaceutical company","created_at":"Sat Jun 13 05:07:43 UTC 2009","updated_at":"Sat Jun 13 05:18:18 UTC 2009","overview":"<p>Hydra Biosciences, a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra&#8217;s proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs.</p>\n\n<p>Hydra&#8217;s ion channel drug discovery program is currently focused on channels implicated in pain, inflammation and cardiovascular disease. Hydra&#8217;s intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium or potassium voltage-gated channels Hydra&#8217;s novel ion channels provide the potential to develop selective and safer ion channel drugs.</p>\n\n<p>Hydra has raised significant financing from blue chip investors since its inception. This prominent group of investors include: Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures. </p>","image":{"available_sizes":[[[150,40],"assets/images/resized/0004/8342/48342v1-max-150x150.png"],[[250,67],"assets/images/resized/0004/8342/48342v1-max-250x250.png"],[[264,71],"assets/images/resized/0004/8342/48342v1-max-450x450.png"]],"attribution":null},"products":[],"relationships":[{"is_past":false,"title":"Chief Operating Officer and Executive Vice President of Development ","person":{"first_name":"Glenn","last_name":"Larsen","permalink":"glenn-larsen","image":{"available_sizes":[[[81,108],"assets/images/resized/0004/8346/48346v1-max-150x150.jpg"],[[81,108],"assets/images/resized/0004/8346/48346v1-max-250x250.jpg"],[[81,108],"assets/images/resized/0004/8346/48346v1-max-450x450.jpg"]],"attribution":""}}},{"is_past":false,"title":"President and Chief Executive Officer","person":{"first_name":"Russell","last_name":"Herndon","permalink":"russell-herndon","image":{"available_sizes":[[[81,108],"assets/images/resized/0004/8344/48344v1-max-150x150.jpg"],[[81,108],"assets/images/resized/0004/8344/48344v1-max-250x250.jpg"],[[81,108],"assets/images/resized/0004/8344/48344v1-max-450x450.jpg"]],"attribution":""}}},{"is_past":false,"title":"Vice President of Finance and Treasurer","person":{"first_name":"Tom","last_name":"Burke","permalink":"tom-burke","image":{"available_sizes":[[[81,108],"assets/images/resized/0004/8347/48347v1-max-150x150.jpg"],[[81,108],"assets/images/resized/0004/8347/48347v1-max-250x250.jpg"],[[81,108],"assets/images/resized/0004/8347/48347v1-max-450x450.jpg"]],"attribution":""}}},{"is_past":false,"title":"Chief Scientific Officer","person":{"first_name":"David","last_name":"Kimball","permalink":"david-kimball","image":{"available_sizes":[[[81,108],"assets/images/resized/0004/8345/48345v1-max-150x150.jpg"],[[81,108],"assets/images/resized/0004/8345/48345v1-max-250x250.jpg"],[[81,108],"assets/images/resized/0004/8345/48345v1-max-450x450.jpg"]],"attribution":""}}}],"competitions":[],"providerships":[],"total_money_raised":"$22M","funding_rounds":[{"round_code":"d","source_url":"http://www.reuters.com/article/pressRelease/idUS118179+16-Jan-2009+BW20090116","source_description":"Hydra Biosciences Raises $22 Million in Series D Financing","raised_amount":22000000,"raised_currency_code":"USD","funded_year":2009,"funded_month":1,"funded_day":16,"investments":[{"company":null,"financial_org":{"name":"MedImmune Ventures","permalink":"medimmune-ventures","image":{"available_sizes":[[[150,34],"assets/images/resized/0004/9449/49449v1-max-150x150.jpg"],[[183,42],"assets/images/resized/0004/9449/49449v1-max-250x250.jpg"],[[183,42],"assets/images/resized/0004/9449/49449v1-max-450x450.jpg"]],"attribution":null}},"person":null}]}],"investments":[],"acquisition":null,"acquisitions":[],"offices":[{"description":"","address1":"790 Memorial Drive, off Pleasant Street","address2":"","zip_code":"02139","city":"Cambridge","state_code":"MA","country_code":"USA","latitude":null,"longitude":null}],"milestones":[],"ipo":null,"video_embeds":[],"screenshots":[{"available_sizes":[[[150,98],"assets/images/resized/0004/8343/48343v1-max-150x150.jpg"],[[250,164],"assets/images/resized/0004/8343/48343v1-max-250x250.jpg"],[[450,296],"assets/images/resized/0004/8343/48343v1-max-450x450.jpg"]],"attribution":null}],"external_links":[]}